SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that David Hung, M.D., president and chief executive officer, will participate in two themed panel discussions at the RBC Capital Markets 2007 Healthcare Conference at The Westin New York at Times Square:
During the panel discussions, Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon(TM) for Alzheimer’s and Huntington’s diseases and MDV3100 for prostate cancer, respectively.
The Company reported results from its Phase 2 efficacy study of Dimebon in Alzheimer’s disease in June 2007, showing that Dimebon improved the clinical course of patients by demonstrating meaningful improvement over placebo in each of the five disease aspects most important to patients, caregivers and physicians -- memory, thinking, activities of daily living, behavior and overall function. Significant gains in these disease aspects were evident as early as the twelfth week of treatment. After six months of treatment, patients were significantly better off than they were at the start of therapy on all key aspects of the disease. Dimebon’s overall benefit compared to placebo continued to increase over time and was greater at 12 months that at six months.
In November 2007, the Company announced early PSA data from the two lowest dose groups in its Phase 1-2 clinical trial of MDV3100 in patients with hormone-refractory prostate cancer. MDV3100 reduced serum PSA levels in all patients enrolled in both dose groups in a dose-dependent manner. In the lowest dose group, after two months of treatment, PSA levels declined 45 percent to 66 percent. PSA levels in the second lowest dose group declined 75 percent to 89 percent after the first month of treatment. MDV3100 has been well-tolerated to date in both dose groups. No dose-limiting toxicities have been identified and dose-escalation continues in the study.
A live audio webcast of each panel will be available on the “Events and Presentations” page of the “Investor Relations” section of the Company’s website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation’s current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer’s disease, Huntington’s disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,
+1-415-829-4101; or Jani Bergan of WeissComm Partners, +1-415-946-1064, for
Medivation, Inc.
Web site: http://www.medivation.com/
